Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 9/20 | 0.42 |
| ▸ | RHOC | P08134 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442326 | 0.91 | TACR1 (0.44) | RHOARHOCTACR1TACR2 | |
| SCHEMBL6442330 | 0.91 | TACR1 (0.44) | RHOARHOCTACR1TACR2 | |
| SCHEMBL5802899 | 0.90 | RHOA (0.54) | RHOARHOCTACR1PROKR1MEN1 | |
| SCHEMBL5802902 | 0.90 | RHOA (0.54) | RHOARHOCTACR1PROKR1MEN1 | |
| SCHEMBL6442173 | 0.90 | KDM1A (0.46) | RHOARHOCTACR1CYP2C9 | |
| SCHEMBL6442171 | 0.90 | KDM1A (0.46) | RHOARHOCTACR1CYP2C9 | |
| SCHEMBL5918091 | 0.90 | TACR1 (0.43) | RHOARHOCTACR1HIF1APROKR1 | |
| SCHEMBL5803870 | 0.90 | HIF1A (0.47) | RHOARHOCTACR1HIF1APROKR1 | |
| SCHEMBL5800732 | 0.90 | TACR1 (0.49) | RHOARHOCTACR1MEN1CYP1A2 | |
| SCHEMBL6442255 | 0.89 | HSD11B1 (0.39) | PROKR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360184-B1 | PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| EP-1360184-A1 | PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-12 | — | — | EP | disclosed |
| US-6642226-B2 | Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062784-A1 | PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151547-A1 | Substituted phenyl-piperidine methanone compounds | TACR1, OPRK1, TACR2 | RHOA 4345/4885RHOC 3239/4885TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.